Cyclin-Dependent Kinase 4
"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
| Descriptor ID |
D051358
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
|
| Concept/Terms |
Cyclin-Dependent Kinase 4- Cyclin-Dependent Kinase 4
- Cyclin Dependent Kinase 4
- Cdk4 Cyclin-Dependent Kinase
- Cdk4 Cyclin Dependent Kinase
- Cyclin-Dependent Kinase, Cdk4
- Cdk4 Protein
- Cdk4 Protein Kinase
- Protein Kinase, Cdk4
- p34PSK-J3 Kinase
- p34PSK J3 Kinase
- Cell Division Protein Kinase 4
- PSK-J3 Kinase
- PSK J3 Kinase
- Cyclin D-Dependent Kinase CDK4
- Cyclin D Dependent Kinase CDK4
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2017 | 3 | 3 | 6 |
| 2018 | 0 | 3 | 3 |
| 2019 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.
-
COVID-19 risk in breast cancer patients receiving CDK4/6 inhibitors: literature data and a monocentric experience. Breast J. 2021 04; 27(4):359-362.
-
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer. Eur J Cancer. 2020 09; 136:99-106.
-
CDK4/6 inhibitors: taking the place of chemotherapy? Lancet Oncol. 2019 10; 20(10):1329-1330.
-
Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. Cancer Treat Rev. 2019 Mar; 74:21-28.
-
Butylene fipronil induces apoptosis in PC12 murine nervous cells via activation of p16-CDK4/6-cyclin D1 and mitochondrial apoptotic pathway. J Biochem Mol Toxicol. 2019 Mar; 33(3):e22264.
-
Different inhibitors for the same target in metastatic luminal breast cancer: is there any difference? Future Oncol. 2018 Apr; 14(9):891-895.
-
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. Expert Opin Pharmacother. 2018 Feb; 19(3):299-305.
-
A novel germline mutation in CDK4 codon 24 associated to familial melanoma. Clin Genet. 2018 04; 93(4):934-935.
-
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treat Rev. 2018 Jan; 62:123-132.
-
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. Curr Opin Oncol. 2017 Nov; 29(6):428-433.